# Long-Chain Fatty Acid Oxidation Disorders In-Clinic Disease Monitoring Program

> **NCT04632953** · — · ACTIVE_NOT_RECRUITING · sponsor: **Ultragenyx Pharmaceutical Inc** · enrollment: 150 (actual)

## Conditions studied

- Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)

## Interventions

- **OTHER:** No Intervention

## Key facts

- **NCT ID:** NCT04632953
- **Lead sponsor:** Ultragenyx Pharmaceutical Inc
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-11-30
- **Primary completion:** 2035-12
- **Final completion:** 2035-12
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2026-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04632953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04632953, "Long-Chain Fatty Acid Oxidation Disorders In-Clinic Disease Monitoring Program". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04632953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*